Fingolimod treatment in Greek patients with multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well fingolimod (Gilenya) works in people with relapsing-remitting multiple sclerosis (RRMS) in Greece. If you're already taking this medication, researchers will review your past medical data to see how it affects your MS over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have relapsing-remitting multiple sclerosis (RRMS), the most common form of MS where symptoms come and go.
- You must already be taking fingolimod (Gilenya), a daily pill that helps reduce MS flare-ups.
- You must have medical records from at least the last 12 months showing your MS history.
- You cannot have any medical reason that makes fingolimod unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
This trial studies whether fingolimod can improve diabetes in adults with type 2 diabetes who are not yet on many medications. It will mainly check whether the drug is safe and whether it can help control blood sugar over time.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
Hear when a new Relapsing Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.